Share Prices & Company Research

Stockbroking

AstraZeneca

Current Price 7256.00p Bid 6200.00p Ask 7500.00p Change -5.60%
Last Updated: 19/08/2019 07:41. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

AstraZeneca plc is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Financial Highlights Year Ended 31/12/2018

Turnover
£22,090.00m
Operating Profit
£3,387.00m
Dividend Yield
3.03
Dividend Per Share
215.20
Dividend Cover
0.78
P/E Ratio
42.53

Key Personnel

Pascal Claude Roland Soriot
Chief Executive Officer
Marc Pierre Jean Dunoyer
Chief Financial Officer
Leif Valdemar Johansson
Non-Executive Chairman
Tony Shu Kam Mok
Non-Executive Director
Marcus Wallenberg
Non-Executive Director
Prof Sabera Nazneen Rahman
Non-Executive Director
Sherilyn Dawn McCoy
Non-Executive Director
Deborah DiSanzo
Non-Executive Director
Graham Andrew Chipchase
Non-Executive Director
Philip Arthur John Broadley
Non-Executive Director
Prof Geneviève Bernadette Berger
Non-Executive Director

Stock Details

EPIC
AZN
ISIN
GB0009895292
Shares in Issue
1,311,876,336
Market cap
£94,848.66m

Analyst Views (11)

Strong Buy
 
45.45%
Buy
 
9.09%
Hold
 
27.27%
Sell
 
0.00%
Strong Sell
 
18.18%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
6850.00p
Bid Price
6200.00p
Ask Price
7500.00p
Volume
0
Change Today
-406.00p
% Change Today
-5.60%
Open
7286.00p
Previous Close
7256.00p
Intraday High
0.00p
Intraday Low
0.00p
52 Week High
7475.00p
52 Week Low
5312.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

AstraZeneca Intra-day Chart

AstraZeneca News

News in this section is provided by AJ Bell

Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC 16 Aug 2019 | 08:30 Broker Forecast - UBS issues a broker note on AstraZeneca PLC 14 Aug 2019 | 09:40 AstraZeneca's leukaemia drug wins fast-track review from US Food and Drug Administration 14 Aug 2019 | 07:21 AstraZeneca and Merck ovarian cancer drug meets primary endpoint in clinical trial 14 Aug 2019 | 07:14 Cocktail of risks sours FTSE 100 performance 09 Aug 2019 | 16:45 FTSE gathers some ground after GDP-inspired fall for the pound 09 Aug 2019 | 12:08 AstraZeneca reveals positive results from trial of lung cancer drug 09 Aug 2019 | 07:46 AstraZeneca and Merck prostate cancer drug meets primary endpoint in clinical trial 07 Aug 2019 | 07:12 Broker Forecast - Goldman Sachs issues a broker note on AstraZeneca PLC 06 Aug 2019 | 09:10 AstraZeneca's type-2 diabetes drug label updated in EU with positive outcomes, data from trial 05 Aug 2019 | 07:33 Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC 29 Jul 2019 | 08:30 Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC 26 Jul 2019 | 09:50 FTSE down as ECB warns on outlook 25 Jul 2019 | 16:43 FTSE dips ahead of possible ECB rate cut 25 Jul 2019 | 11:58 UK stocks rise ahead of ECB interest rate decision 25 Jul 2019 | 09:38 AstraZeneca lifts product sales guidance amid stronger H1 25 Jul 2019 | 07:31 FTSE regains its poise by lunchtime 15 Jul 2019 | 12:07 UK stocks open slightly higher after mixed Chinese economic data 15 Jul 2019 | 08:57 AstraZeneca's Type-1 diabetes treatment fails to get FDA approval 15 Jul 2019 | 07:42 AstraZeneca's lung cancer treatment granted Orphan Drug Designation 12 Jul 2019 | 07:43 Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC 08 Jul 2019 | 09:10 FTSE closes higher as S&P 500 hits new record 01 Jul 2019 | 16:59 AstraZeneca receives positive opinion from European regulators to add self-administration option to asthma drug 01 Jul 2019 | 08:47 AstraZeneca's type-2 diabetes drug receives positive opinion from European regulators for cardiovascular outcomes 01 Jul 2019 | 08:17 FTSE 100 reverses gains amid growing nervousness as key summit gets underway 27 Jun 2019 | 12:19 UK stocks rise ahead of G20 summit 27 Jun 2019 | 09:33 AstraZeneca says lung cancer drug met primary goal 27 Jun 2019 | 07:56 FTSE slips as sterling surges on rate speculation 19 Jun 2019 | 16:41 Stocks marking time until crunch Fed meeting 19 Jun 2019 | 12:12 AstraZeneca, Merck ovarian cancer drug wins approval from Japanese regulators 19 Jun 2019 | 07:23

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
7,421.0
7,615.0
Intangible Assets & Goodwill
33,666.0
38,013.0
Investments & Other Non-Current Assets
3,973.0
4,576.0
Total Non-Current Assets
45,060.0
50,204.0
Inventory
2,890.0
3,035.0
Trade & Receivables
5,574.0
5,009.0
Cash & Receivables
4,831.0
3,324.0
Other Current Assets & Assets Held for Resale
2,296.0
1,782.0
Total Assets
60,651.0
63,354.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
16,292.0
16,383.0
Long Term Liabilities
30,315.0
30,329.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
46,607.0
46,712.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
14,044.0
16,642.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
317.0
317.0
Minority Interests
1,576.0
1,682.0
Retained Earnings
5,683.0
8,221.0
Share Premium Account
4,427.0
4,393.0
Other Equity
2,041.0
2,029.0
Total Equity
14,044.0
16,642.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
2,618.0
3,578.0
Cashflow Before Financing
3,581.0
1,250.0
Increase / Decrease in Cash
1,537.0
-1,686.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
22,090.0
22,465.0
Cost of Sales
4,936.0
4,318.0
Gross Profit
17,154.0
18,147.0
Operating Profit
3,387.0
3,677.0
Pre-Tax Profit
1,993.0
2,227.0
Profit / Loss for the Year
2,050.0
2,868.0

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H1 Dividend
08 Aug 2019
09 Sep 2019
H2 Dividend
28 Feb 2019
27 Mar 2019
H1 Dividend
09 Aug 2018
10 Sep 2018
H2 Dividend
15 Feb 2018
19 Mar 2018
H1 Dividend
10 Aug 2017
11 Sep 2017
H2 Dividend
16 Feb 2017
20 Mar 2017
H1 Dividend
11 Aug 2016
12 Sep 2016
H2 Dividend
18 Feb 2016
21 Mar 2016
H1 Dividend
13 Aug 2015
14 Sep 2015
H2 Dividend
19 Feb 2015
23 Mar 2015
H1 Dividend
13 Aug 2014
15 Sep 2014
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.